Compare Medline Inc. Class A Common Stock (MDLN) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medline Inc. Class A Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Medline Inc. Class A Common Stock trades at $36 (market cap $31.32B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Medline Inc. Class A Common Stock is far larger — about 21.2× uniQure N.V. Ordinary Shares's market cap, and Medline Inc. Class A Common Stock is more actively traded (4,364,703 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold Medline Inc. Class A Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MDLN | QURE | |
|---|---|---|
Market Cap | $31.32B | $1.48B |
Volume | 4,364,703 | 2,488,780 |
Sector | Health | Health |
52-Week High | $49.99 | $70.59 |
52-Week Low | $31.64 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $41.28B | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
